LEADER 01547oam  2200421Ia 450 
001 9910699292803321
005 20230902161640.0
035   $a(CKB)5470000002400974
035   $a(OCoLC)469784519
035   $a(EXLCZ)995470000002400974
100   $a20091125d2001      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $eproviding regulatory submissions in electronic format, prescription drug advertising and promotional labeling
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation :$cCenter for Biologics Evaluation and Research,$d[2001]
215   $a1 online resource (5 pages)
300   $a"Draft guidance."
300   $a"IT."
300   $a"January 2001."
517   $aGuidance for industry 
606   $aElectronic records
606   $aAdvertising$xDrugs$xGovernment policy$zUnited States
606   $aDrugs$xLabeling$xGovernment policy$zUnited States
615  0$aElectronic records.
615  0$aAdvertising$xDrugs$xGovernment policy
615  0$aDrugs$xLabeling$xGovernment policy
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910699292803321
996   $aGuidance for industry$93434577
997   $aUNINA